Diabetic Nephropathy (Disease Or Phenotype)

Nci:C84417

Msh:D003928

Mondo:MONDO:5016

Medcin:MEDCIN:314780

Mdr:MDR:10012678

Id:96b85851-9eaf-5248-b031-76c0cdbb55a6

Icpc2icd10eng:MTHU052076

Efo:EFO:401

Chv:CHV:3845

Linked to

	Label	Description
	1-(3-Mercapto-2-methyl-propionyl)-pyrrolidine-2-carboxylic acid indication Diabetic Nephropathy Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from IDG
	LOSARTAN indication Diabetic Nephropathy Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from IDG
	1-(2-hydroxyethyl)-4-methyl-N-(4-(methylsulfonyl)phenyl)-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxamide indication Diabetic Nephropathy Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from IDG
	2-Butyl-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-1,3-diaza-spiro[4.4]non-1-en-4-one indication Diabetic Nephropathy Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from IDG

1-(3-Mercapto-2-methyl-propionyl)-pyrrolidine-2-carboxylic acid indication Diabetic Nephropathy

A Knowledge Graph Assertion from IDG

LOSARTAN indication Diabetic Nephropathy

A Knowledge Graph Assertion from IDG

1-(2-hydroxyethyl)-4-methyl-N-(4-(methylsulfonyl)phenyl)-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxamide indication Diabetic Nephropathy

A Knowledge Graph Assertion from IDG

2-Butyl-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-1,3-diaza-spiro[4.4]non-1-en-4-one indication Diabetic Nephropathy

A Knowledge Graph Assertion from IDG

DISPLAY PER PAGE

@CFDE Workbench 2025

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2025